Efficacy and Safety of Triple Fixed Dose Combination of Dapagliflozin + Sitagliptin + Metformin IR in Indian Patients with Type 2 Diabetes Mellitus: A Randomized, Phase 3 Study in Comparison with Dual FDC Sitagliptin + Metformin IR.

Adv Ther · 2025 · PMC12474733 · PMID 40828352

Europe PMC DOI

hedged sentence

0.0554

closest p · 1.1× alpha

0.0554

boldest claim

The sentences

did not reach statistical significanceP = 0.0554so close (0.05 < p ≤ 0.1)

By Week 16, the reduction was numerically greater in the triple FDC arm but did not reach statistical significance (– 55.3 ± 78.20 mg/dl vs – 47.2 ± 74.87 mg/dl; P = 0.0554) (Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.